New approaches for G-protein coupled receptor ligands identification. doi: http://dx.doi.org/10.5016/1806-8774.2009v11pT95

Authors

  • Andrea Heimann Proteimax Biotechnology, 06713-330, Cotia
  • Emer Ferro Department of Cell Biology and Development, Institute of Biomedical Sciences, University of São Paulo

DOI:

https://doi.org/10.5016/1806-8774.2009v11pT95

Abstract

G protein-coupled receptors (GPCRs) represent the class of proteins with the highest impact from social, therapeutic and economic point of view. Today, more than 50% of drug targets are based on GPCRs and the annual worldwide sales exceeds 50 billion dollars. GPCRs are involved in all major diseases areas such as cardiovascular, metabolic, neurodegenerative, psychiatric, cancer and infectious diseases. The classical drug discovery process has relied on screening compounds, which interact favorably with the GPCR of interest followed by further chemical engineering as a mean of improving efficacy and selectivity. On the other hand, several new peptides with potential bioactivity are discovery every year. This review will focus on recent advancement on methods for identification of novel peptides with potential ability to activate GPCRs.

Author Biographies

Andrea Heimann, Proteimax Biotechnology, 06713-330, Cotia

Proteimax Biotechnology, 06713-330, Cotia, SP, Brazil.

Emer Ferro, Department of Cell Biology and Development, Institute of Biomedical Sciences, University of São Paulo

Department of Cell Biology and Development, Institute of Biomedical Sciences, University of São Paulo, 05508-900, São Paulo, SP, Brazil

Downloads

Published

2010-02-21

Issue

Vol. 11 (2009)

Section

Theme Topic on "Cell Receptors and Signaling"

License

Disclaimer The Publisher does not assume responsibility for any injury and/or damage to persons or property as a matter of product liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the reviews published by ARBS. All procedures reported are expected to conform to ethical standards; inclusion in the journal does not constitute a guarantee or endorsement of the quality or value of such procedures. Copyright Submission of a review to this periodical will be taken to imply that it represents an original unpublished text, not under consideration for publication elsewhere. Written permission to publish illustrations must be obtained by the corresponding author before submission and any acknowledgment should be included in figure captions. Terminology: Abbreviations, Acronyms, Eponyms, and Nomenclature - Define ALL abbreviations, acronyms and names of genes, gene products, proteins, and protein products at first mention. Do not use abbreviations in titles. Only universally accepted abbreviations may be used without definition. - Observe species-appropriate rules of nomenclature formatting with respect to use of upper and lower case letters and italics for both gene and protein designations. - Avoid beginning sentences with very short abbreviations or acronyms, especially those that begin with a lower case letter (such as hCG, mRNA, etc.; use “Human CG”, “Messenger RNA”, etc., in the latter instances). - Do not use the possessive form in eponymous terms: use Dulbecco Modified Eagle medium, not Dulbecco's Modified Eagle's medium; Hanks solution, not Hanks' solution; etc.